Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Huntington’s disease
Biotech
FDA grants uniQure priority review of its Huntington’s drug
Despite a tumultuous recent run with the FDA, uniQure believes an approval in May 2027 would be a “defining milestone.”
Marissa Russo
Nov 2, 2026 4:12pm
uniQure stock crashes as Huntington’s gene therapy data weaken
Sep 29, 2026 9:28am
Roche ends 2 Huntington’s programs, including Ionis ASO
Jul 9, 2026 2:40pm
Can’t plausible mechanism principles apply to uniQure?
Apr 15, 2026 4:00am
Senior FDA official fires back at uniQure amid controversy
Mar 5, 2026 3:33pm
UniQure, FDA back-and-forth intensifies
Mar 5, 2026 11:55am